Company intelligence / Profile preview

EFEVRE TECH

Larnaca, Larnaca District, Cyprusefevre.com ↗

Ownership: Private
Development stage: Commercial

Overview

EFEVRE TECH has successfully commercialized its flagship AMGEL device—an autonomous robotic system that automates multiple lab procedures to reduce human error and improve reproducibility in scientific research. The system is already adopted by prestigious institutions like the University of Cambridge’s Cancer Molecular Diagnostics Lab and the Agricultural Research Institute of Cyprus. The company has secured significant grants from the Research and Innovation Foundation of Cyprus and filed multiple patents.

Modalities: DeviceArtificial Intelligence-powered software platform
Industry: Non-Drug Biotech

Partnerships

University of Cambridge Cancer Molecular Diagnostics LabAgricultural Research Institute of Cyprus

Beyond the preview

Go deeper on EFEVRE TECH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EFEVRE TECH.

Explore the full profile